Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | YAP1 | P46937 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | USP19 | O94966 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385886 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL25426557 | 0.95 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL6892070 | 0.91 | GRIN2B (0.50) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL20339027 | 0.91 | PARP1 (0.46) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL4400064 | 0.90 | FAAH (0.49) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132096 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132098 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132404 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL25295183 | 0.87 | YAP1 (0.46) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL30288951 | 0.86 | DRD2 (0.52) | SMN1; SMN2NPC1RAB9AHTTUSP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-6335341-B1 | ANTICHOLESTEROL AGENTS; ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-1000057-A1 | PYRIDYL- AND PYRIMIDYL-HETEROCYCLIC COMPOUNDS INHIBITING OXIDO SQUALENE-CYCLASE | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006395-A1 | PYRIDYL- AND PYRIMIDYL-HETEROCYCLIC COMPOUNDS INHIBITING OXIDO SQUALENE-CYCLASE | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | SMN1; SMN2 4482/4885NPC1 3129/4885RAB9A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.